BioClonetics Immunotherapeutics

Our Progress is Continuing

Thanks to all our new investors and our many initial investors, we are making great progress toward the preparation of our anti-HIV monoclonal antibody for animal and clinical trials.  We want to share the latest information on our advancements. 

- As described below, our progress toward producing the recombinant of our anti-HIV monoclonal antibody is ongoing – bringing us closer to animal and clinical trials.

- Our negotiations with Serum Institute (www.seruminstitute.com) are progressing toward an agreement that will carry our program to animal and clinical trials from the completion of production of the recombinant of our antibody.

Our anti-HIV antibody works by binding to a specific portion of the HIV virus (the Achilles heel of the virus) and as a result, our antibody neutralizes the virus (making it incapable of infecting the human cell).  By analogy, image an explosive being launched at a target.  If the explosive is intercepted before reaching the target, the target is protected from destruction.  This is what our antibody does – it attaches to the virus preventing it from binding to and entering the human body CD+4 cell.  

Here’s is where we are now and how your investment is being used:

The antibody is being engineered into a form (called the recombinant) that will be producible in sufficient quantities for patient application to the millions who can benefit from the antibody.  To create this recombinant, we much identify the amino acid sequence of the antibody and from that sequence the recombinant will be produced and then tested in animal and human trials.

We know that our antibody contains a total of 1346 amino acids.  It is composed of 2 chains, called a heavy chain and a light chain intertwined.

From substantial prior analysis at 3 separate labs located around the world (Nissin Laboratories Japan, Antitope (Abzena) UK, and Polymun Austria), we have confirmed the amino acid sequence for the antibody heavy chain and have identified all 918 amino acids making up the heavy chain.

As for the other part of our antibody, the light chain, it is made of 214 amino acids.  Of these 214 amino acids, we have confirmed all but 13 amino acids.

Because of the importance of accurately identifying the full amino acid sequence before proceeding with production of the recombinant and then testing against strains of the virus followed by animal and clinical trials, we are completing analysis in three independent laboratories using 3 distinct methods of identification of the remaining amino acids in the light chain.  This analysis is being conducted in these labs:

 ·         - STC Biologics – PCR sequence determination of Clone 3 light chain identification by random hexamers Plus PCR; 
 ·         - Rapid Novor – Light chain identification using Mass Spec analysis on purified Clone 3 antibody; and
 ·         - Novo Gene – Using the company’s New Generation Sequencing (NGS) technique to identify the sequence of the light chain.

Once the full sequence amino acid sequence is confirmed the recombinant antibody will be produced, then tested and then carried forward to animal and clinical trials.

We will keep you apprised of all developments and extend our appreciation for your confidence in our technology and goal.  We invite new investors to join us.  For more details about our technology and its value, we invite you to view our website www.bioclonetics.com

Liked by Patrick REDDY, Brian Buttrey, Dilraj Ghumman, and 14 others